SCHEDULE: Andera Partners Reduces Mineralys Therapeutics Stake
Beneficial Ownership Report
Andera Partners and affiliates report a reduced beneficial ownership of Mineralys Therapeutics, Inc. common stock to 4.2%.
Summary
- Andera Partners, BioDiscovery 6 FPCI, Stephane Bergez, and Francois Xavier Mauron (collectively, the "Reporting Persons") have filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership of Mineralys Therapeutics, Inc. common stock.
- As of June 30, 2025, the Reporting Persons collectively beneficially own 2,765,976 shares of Mineralys Therapeutics, Inc. common stock.
- This ownership represents 4.2% of the outstanding common stock, based on 65,175,287 shares outstanding as of May 8, 2025.
- BioDiscovery 6 FPCI is the record holder of the shares, with voting and dispositive decisions made by its management company, Andera Partners.
- Stephane Bergez and Francois Xavier Mauron are managing partners of Andera Partners and are deemed to beneficially own the securities held by BioDiscovery 6 FPCI.
- The Reporting Persons are all citizens or entities organized in France.
- The filing indicates that the Reporting Persons now own 5% or less of the class, implying a reduction from a previous stake that was 5% or more.
Sentiment
Score: 4
Explanation: The sentiment is slightly negative due to a significant investor reducing their stake below the 5% threshold, which can be interpreted as a decrease in conviction, though it is a compliance filing rather than an operational update.
Negatives
- The beneficial ownership stake of the Reporting Persons has decreased to below 5%, which could be interpreted by the market as reduced conviction or a strategic divestment by a significant investor.
Future Outlook
NA
Industry Context
This filing is a routine disclosure of a change in beneficial ownership by an institutional investor in a publicly traded biotechnology or pharmaceutical company. Such changes are common and reflect portfolio adjustments or strategic decisions by investors.
Stakeholder Impact
- Shareholders may perceive the reduction in stake by a significant investor as a negative signal, potentially influencing stock price.
Key Dates
| Date | Description |
|---|---|
| 05/08/2025 | Date as of which 65,175,287 shares of common stock were reported outstanding in the Issuer's Quarterly Report on Form 10-Q. |
| 06/30/2025 | Date of event which required the filing of this statement. |
| 08/14/2025 | Date of execution of the Joint Filing Agreement and signing of the Schedule 13G. |
Keywords
Mineralys Therapeutics, Andera Partners, BioDiscovery 6 FPCI, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor, Shareholding, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.